THE NORGANOID
PLATFORM

With the help of our NanoLab System (NLS™ ) we envision a future where organoids reduce the cost of failure of preclinical studies and improve clinical outcomes, possibly leading to better and more affordable drugs.

At NORGANOID, we get the challenges of organoid generation and how crucial it is to have realistic disease models for drug development. That is why we have come up with our Organoids-as-a-Service (OaaS) program – a one-stop solution that handles everything from initial cell procurement to differentiation and final to the delivery of the organoids.

Nanolab
System

We are developing a scalable, automated, and high-content screening OoC platform. Our system will provide you with a robust solution  for exploring complex biological processes, reducing manual work, and evaluating the efficacy of new therapies in a clinically relevant context.

Going from 2D to 3D
Our NLS™ will take over the challenging process of organoid generation, in vitro drug screening and imaging for customers that want to expand their portfolio of preclinical drug testing methods beyond conventional 2D cell cultures or animal models.
Plug-and-play Solution
NLS™ is designed as a plug-and-play solution that handles everything from initial iPSC differentiation to organoid culture maintenance. Its format is compatible with standard imaging techniques and can be easily used for phenotypic screening. We are currently developing our platform to work for brain, liver and endometrial organoids.
Cost-Efficiency
Unlike traditional automated cell culture systems , our microfluidics-based organ-on-chip platform will present significant cost advantages. With the ability to process large organoid samples while reducing reagent consumption, our system will minimize capital expenditures compared to prevailing robotic solutions. It represents a cost-effective option for a wide range of applications in the field of drug and chemical screening.
Enabling R&D Goals
Our pioneering technology enables unmatched drug screening possibilities, cost-effectiveness, and an unwavering dedication to continuous improvement. Connect with us today to explore how our solutions can enhance your research and development endeavours.
Flexible Cell Options
Choose between utilizing your own induced pluripotent stem cells (iPSCs), differentiated cells, or patient tissue-derived cells, or explore our library of supplier cells. This flexibility guarantees access to the most pertinent cell sources for your specific research and development goals.
Careful Control of Differentiation
Our seasoned scientists meticulously regulate the differentiation process, producing organoids at the precise differentiation stage required for your research.
Simplified Workflow
With our OaaS program, you can focus on your research while we handle all the details of organoid generation – from cell culture to quality control to delivery.

Organoid-FactoryTM
AS-a-Service

Coming soon.

HOW TO WORK WITH US

We are actively looking for commercial partners with the interest in collaborating on research projects within the brain, liver and endometrial organoid space via joint venture and in-licensing agreements.

Contact US
Subscribe to stay up to date!

NORGANOID GmbH